Modulation of cell-mediated immunity with 5-azapyrimidine nucleosides. 1987

K Sůla, and K Nouza, and J Madar, and A Cihák
Institute of Experimental Medicine, Czechoslovak Academy of Sciences, Prague.

5-azacytidine [5-AzCR] and 5-aza-2'-deoxycytidine [5-AzCdR] can produce an immunosuppressive or an immunostimulatory effect on the graft-versus-host or host-versus-graft reactions in the regional popliteal lymph node of the mouse. The result depends on the dose of the drug and the time between its administration and induction of the cell-mediated immune response. Syngeneic spleen cells are capable of inducing regional lymphadenomegaly if injected into the footpads of recipients treated 1 day previously or concurrently with 5-AzCR or 5-AzCdR. Spleen cells from allogeneic and syngeneic donors treated with 5-AzCR or 5-AzCdR in vivo or in vitro can elicit greater regional lymphadenomegaly than the untreated cells. Both drugs not only seem to influence the proliferative activity of effector and regulatory populations of immunocompetent cells, but they probably also change their recognition ability and immunogenic properties.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D006087 Graft vs Host Reaction An immunological attack mounted by a graft against the host because of HISTOINCOMPATIBILITY when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE. HLA Sensitization,Human Leukocyte Antigen Sensitization,Sensitization, HLA
D006789 Host vs Graft Reaction The immune responses of a host to a graft. A specific response is GRAFT REJECTION.
D000077209 Decitabine An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA. 2'-Deoxy-5-azacytidine,5-Aza-2'-deoxycytidine,5-AzadC,5-Azadeoxycytidine,5-Deoxyazacytidine,5AzadC,AzadC Compound,Dacogen,Decitabine Mesylate,NSC 127716,NSC-127716,2' Deoxy 5 azacytidine,5 Aza 2' deoxycytidine,5 Azadeoxycytidine,5 Deoxyazacytidine,Compound, AzadC,Mesylate, Decitabine,NSC127716
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001374 Azacitidine A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent. Azacytidine,5-Azacytidine,NSC-102816,Vidaza,5 Azacytidine,NSC 102816,NSC102816
D013154 Spleen An encapsulated lymphatic organ through which venous blood filters.

Related Publications

K Sůla, and K Nouza, and J Madar, and A Cihák
August 1982, Immunobiology,
K Sůla, and K Nouza, and J Madar, and A Cihák
January 1987, Nucleic acids symposium series,
K Sůla, and K Nouza, and J Madar, and A Cihák
March 2000, Nucleosides, nucleotides & nucleic acids,
K Sůla, and K Nouza, and J Madar, and A Cihák
January 1985, Advances in enzyme regulation,
K Sůla, and K Nouza, and J Madar, and A Cihák
May 1970, FEBS letters,
K Sůla, and K Nouza, and J Madar, and A Cihák
January 1994, Zeitschrift fur Naturforschung. C, Journal of biosciences,
K Sůla, and K Nouza, and J Madar, and A Cihák
January 1987, Annals of the New York Academy of Sciences,
K Sůla, and K Nouza, and J Madar, and A Cihák
January 2016, Beilstein journal of organic chemistry,
K Sůla, and K Nouza, and J Madar, and A Cihák
April 1978, Biochimica et biophysica acta,
K Sůla, and K Nouza, and J Madar, and A Cihák
January 1975, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!